Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 7/20 | 0.37 |
| ▸ | FEN1 | P39748 | 7/20 | 0.37 |
| ▸ | PDE4A | P27815 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21220030 | 1.00 | ALOX5AP (0.37) | ALOX5APFEN1PDE4AKCNH2JAK2 | |
| SCHEMBL19784180 | 0.93 | PDE4A (0.36) | PDE4AKCNH2GSK3B | |
| SCHEMBL19784041 | 0.91 | PDE4A (0.34) | PDE4AKCNH2GSK3B | |
| SCHEMBL20969297 | 0.90 | PDE4A (0.34) | PDE4AKCNH2GSK3B | |
| SCHEMBL19784156 | 0.90 | PDE4A (0.34) | PDE4AKCNH2GSK3B | |
| SCHEMBL20969353 | 0.89 | GSK3B (0.35) | PDE4AKCNH2GSK3BDYRK1A | |
| SCHEMBL20969329 | 0.89 | PDE4A (0.35) | PDE4AKCNH2NTRK1 | |
| SCHEMBL19784014 | 0.89 | GSK3B (0.35) | PDE4AKCNH2GSK3BDYRK1A | |
| SCHEMBL19784013 | 0.89 | GSK3B (0.35) | PDE4AKCNH2GSK3BDYRK1A | |
| SCHEMBL19784018 | 0.88 | PDE4A (0.33) | PDE4AKCNH2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3481823-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | ALOX5AP 1831/4885FEN1 3608/4885PDE4A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.